Reduction of cardiovascular events using losartan? - The LIFE study

被引：0
|
作者：
Schunkert, H [1 ]
机构：
[1] Univ Klinikum Lubeck, Med Klin 2, D-23538 Lubeck, Germany
来源：
INTERNIST | 2003年 / 44卷 / 03期
关键词：
D O I：
10.1007/s00108-003-0865-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：367 / 370
页数：4
相关论文
共 50 条
  • [1] Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients -: Losartan intervention for endpoint reduction in hypertension study
    Ibsen, H
    Olsen, MH
    Wachtell, K
    Borch-Johnsen, K
    Lindholm, LH
    Mogensen, CE
    Dahlöf, B
    Devereux, RB
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Lederballe-Pedersen, O
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wan, Y
    [J]. HYPERTENSION, 2005, 45 (02) : 198 - 202
  • [2] Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy -: The LIFE (losartan intervention for endpoint reduction in hypertension) study
    de Simone, G
    Wachtell, K
    Palmieri, V
    Hille, DA
    Beevers, G
    Dahlöf, B
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Julius, S
    Kjeldsen, SE
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Devereux, RB
    [J]. CIRCULATION, 2005, 111 (15) : 1924 - 1931
  • [3] Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Ruwald, Anne Christine H.
    Westergaard, Bo
    Sehestedt, Thomas
    Kjeldsen, Sverre E.
    Lindholm, Lars H.
    Wachtell, Kristian
    Devereux, Richard B.
    Ibsen, Hans
    Nieminen, Markku S.
    Dahlof, Bjorn
    Olsen, Michael H.
    [J]. JOURNAL OF HYPERTENSION, 2012, 30 (06) : 1252 - 1259
  • [4] Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
    Kjeldsen, Sverre E.
    Devereux, Richard B.
    Hille, Darcy A.
    Lyle, Paulette A.
    Dahlof, Bjorn
    Julius, Stevo
    Edelman, Jonathan M.
    Snapinn, Steven M.
    De Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hans
    Lederballe-Pedersen, Ole
    Lindholm, Lars H.
    Nieminen, Markku S.
    Omvik, Per
    Oparil, Suzanne
    Wedel, Hans
    [J]. BLOOD PRESSURE, 2009, 18 (06) : 348 - 361
  • [5] Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study
    Cruickshank, JM
    [J]. LANCET, 2002, 359 (9324): : 2200 - 2201
  • [6] The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Fossum, E
    Moan, A
    Kjeldsen, SE
    Devereux, RB
    Julius, S
    Snapinn, SM
    Edelman, JM
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristianson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Dahlöf, B
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) : 770 - 775
  • [7] A Point System Table to Estimate the Risk of Cardiovascular Events in Patients With Hypertension and Left Ventricular Hypertrophy. The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Hille, Darcy
    Kjeldsen, Sverre E.
    Dahloef, Bjoern
    Edelman, Jonathan M.
    Devereux, Richard B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A214 - A214
  • [8] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
    Dahlöf, B
    Devereux, RB
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    [J]. LANCET, 2002, 359 (9311): : 995 - 1003
  • [9] Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension -: A losartan intervention for endpoint-reduction in hypertension (LIFE) substudy
    Olsen, MH
    Wachtell, K
    Bella, JN
    Palmieri, V
    Gerdts, E
    Smith, G
    Nieminen, MS
    Dahlöf, B
    Ibsen, H
    Devereux, RB
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (11) : 1430 - 1436
  • [10] Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study
    Devereux, RB
    Lyle, PA
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (11) : 2311 - 2320
12345